Beigene (NASDAQ:ONC) Stock Price Up 11.8% – Should You Buy?

Shares of Beigene, Ltd. (NASDAQ:ONC) shot up 11.8% during trading on Friday . The stock traded as high as $234.80 and last traded at $232.86. 146,144 shares traded hands during trading, a decline of 69% from the average session volume of 474,178 shares. The stock had previously closed at $208.31.

Analyst Ratings Changes

ONC has been the subject of a number of research analyst reports. Guggenheim reissued a “buy” rating and set a $348.00 target price on shares of Beigene in a research report on Thursday. Sanford C. Bernstein set a $259.00 price target on Beigene in a report on Thursday, March 13th. Macquarie lifted their price objective on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Royal Bank of Canada initiated coverage on Beigene in a report on Monday, April 7th. They set an “outperform” rating and a $312.00 target price on the stock. Finally, JMP Securities set a $348.00 price objective on shares of Beigene in a research note on Friday, February 28th.

Beigene Price Performance

The company has a fifty day moving average price of $246.33. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The stock has a market cap of $22.73 billion, a P/E ratio of -27.96, a price-to-earnings-growth ratio of 7.73 and a beta of 0.49.

Beigene (NASDAQ:ONC) last released its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Equities research analysts forecast that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.

Insider Activity at Beigene

In related news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $258.04, for a total transaction of $310,164.08. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the company’s stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the completion of the sale, the director now directly owns 730,642 shares in the company, valued at approximately $189,966,920. The trade was a 50.07 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,104,288 shares of company stock valued at $285,064,819. Insiders own 7.43% of the company’s stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.